Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

Autor:	Reinhard Hartmann, Andrea Biondi, Giovanni Cazzaniga, Günter Henze, Cornelia Eckert, Michael Pogodda, Jutta Proba, Birgit Beyermann, Karlheinz Seeger
Rok vydání:	2001
Předmět:	Male Oncology medicine.medical_specialty Neoplasm Residual medicine.medical_treatment Antineoplastic Agents Hematopoietic stem cell transplantation Polymerase Chain Reaction Disease-Free Survival Predictive Value of Tests hemic and lymphatic diseases Internal medicine Acute lymphocytic leukemia medicine Humans Child Retrospective Studies Chemotherapy business.industry Hematopoietic Stem Cell Transplantation Retrospective cohort study General Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis medicine.disease Minimal residual disease Surgery El Niño Predictive value of tests Lymphoblastic leukaemia Female business
Zdroj:	The Lancet. 358:1239-1241
ISSN:	0140-6736
DOI:	10.1016/s0140-6736(01)06355-3
Popis:	Molecular monitoring by quantitative PCR techniques of residual leukaemia cells during the first phases of treatment can predict outcome in children with acute lymphoblastic leukaemia. We did a retrospective study of 30 children who had been treated according to the ALL-REZ BFM trials to assess whether amount of minimal residual disease during the first stages of treatment for relapsed acute lymphoblastic leukaemia could predict outcome. In children with minimal residual disease of less than 10(-3) at day 36, probability of event-free survival was 0.86 (95% CI 0.77-0.95), compared with 0 in children with minimal residual disease of 10(-3) or greater (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fdf5ed10037ee1b0258f825f54274e8 https://doi.org/10.1016/s0140-6736(01)06355-3 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.